Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06478251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 9 → 18 participants Show 6 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion date changed from estimate of Jun 2026 to Jun 19, 2025
    • Eligibility criteria expanded, about 15 words
    • Secondary endpoints: 2 to 8
    • Study description revised
    • Site details revised
  2. Re-verified, no change to tracked fieldsv3
  3. Start date: Mar 31, 2024 to Feb 1, 2024v2 Show 4 more changesShow less
    • Eligibility criteria shortened, about 245 words
    • Secondary endpoints expanded, about 8 words
    • Study description expanded, about 46 words
    • Study title expanded, about 11 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
Trial Details
NCT Number NCT06478251
Lead Sponsor TingBo Liang
Collaborators: Neowise Biotechnology
Conditions
(from sponsor)		 Tumor, Solid
Related terms Neoplasms
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov